Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use

Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and...

Descripción completa

Detalles Bibliográficos
Autores principales: Pacheco, Curtis S, White, Kevin M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174336/
https://www.ncbi.nlm.nih.gov/pubmed/37182063
http://dx.doi.org/10.7759/cureus.37441
_version_ 1785040006562185216
author Pacheco, Curtis S
White, Kevin M
author_facet Pacheco, Curtis S
White, Kevin M
author_sort Pacheco, Curtis S
collection PubMed
description Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and ocular surface reactions; however, a variety of both acute and delayed cutaneous reactions have also been described. We present a case of delayed hyperpigmented injection site reactions following chronic dupilumab use.
format Online
Article
Text
id pubmed-10174336
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101743362023-05-12 Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use Pacheco, Curtis S White, Kevin M Cureus Dermatology Dupilumab is a humanized monoclonal antibody approved for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), asthma, atopic dermatitis, eosinophilic esophagitis, and prurigo nodularis. The most common adverse reactions from dupilumab use are temporary injection site reactions and ocular surface reactions; however, a variety of both acute and delayed cutaneous reactions have also been described. We present a case of delayed hyperpigmented injection site reactions following chronic dupilumab use. Cureus 2023-04-11 /pmc/articles/PMC10174336/ /pubmed/37182063 http://dx.doi.org/10.7759/cureus.37441 Text en Copyright © 2023, Pacheco et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Pacheco, Curtis S
White, Kevin M
Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use
title Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use
title_full Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use
title_fullStr Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use
title_full_unstemmed Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use
title_short Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use
title_sort delayed hyperpigmented injection site reactions due to chronic dupilumab use
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174336/
https://www.ncbi.nlm.nih.gov/pubmed/37182063
http://dx.doi.org/10.7759/cureus.37441
work_keys_str_mv AT pachecocurtiss delayedhyperpigmentedinjectionsitereactionsduetochronicdupilumabuse
AT whitekevinm delayedhyperpigmentedinjectionsitereactionsduetochronicdupilumabuse

Ejemplares similares